Bavarian Nordic gains US patent for its proprietary vaccine technology  

The US Patent and Trademark Office has issued a patent for Bavarian Nordic's core MVA-BN vaccine technology

Biopharmaceutical company Bavarian Nordic has been granted a patent by the US Patent and Trademark Office for its MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) vaccine technology. The patent will protect Bavarian Nordic's smallpox vaccine Imvamune. The Danish company has also been granted a patent for using MVA-BN to develop vaccines for the treatment of diseases such as HIV, Yellow Fever and Japanese pneumonia.


Peter Wulff, managing director of Bavarian Nordic says that the issuing of this broad patent on the MVA-BN virus and its derived strains, makes it difficult for others to develop and produce a safe and efficient MVA based vaccine without a licence. Bavarian Nordic announced last week that it had entered a global cooperation agreement with GlaxoSmithKline on production and marketing of Imvamune. The news is reported by professional journal Ingeniøren (the Engineer).


Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×